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The majority of randomised clinical trials that have established R-CHOP-21 as the current 
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standard treatment for adult patients with diffuse large B-cell lymphoma (DLBCL) have 
applied eight cycles of chemotherapy [1-3]. Despite a lack of solid evidence to support the use 
of six instead of eight cycles of R-CHOP-21, six cycles are commonly assigned in clinical 
routine and endorsed in guidelines. 
No randomised trial has demonstrated superiority of eight compared to six cycles of R-
CHOP-21. Therefore, we examined whether the use of six versus eight cycles of R-CHOP-21 
had impact on survival probability, using data from the Danish and Swedish lymphoma 
registries, as previously described [4].  
This study includes 1170 adult patients diagnosed with DLBCL 2007-2014 in Sweden and 
Denmark, who received treatment with six or eight cycles of R-CHOP-21. Of these, 1013 
(87%) were administered six cycles, and 157 (13%) received eight cycles. Median follow-up 
time was 5.0 years (range 1.2-9.4). 
Reflecting the population-based setting, patient characteristics in the two treatment groups 
slightly differed, and were marginally inferior in the cohort treated with eight cycles of R-
CHOP-21. In survival estimates, crude five-year overall survival (OS) rates were similar for 
patients treated with six and eight cycles of R-CHOP-21; 74% (95% CI: 71-77%) and 72% 
(95% CI: 63-79%), respectively (Figure 1). Further, in a multivariate Cox model adjusting for 
IPI variables and gender, eight cycles of R-CHOP-21 was not associated with better outcome 
than six cycles (HR: 0.92, 95% CI: 0.66-1.29, P=0.63).  
To further adjust for imbalances in prognostic factors, a matched sample analysis was 
performed. Here, the 157 patients who received eight cycles were compared to 157 patients 
who received six cycles of chemotherapy, matched according to IPI variables and bulky 
disease. Similar five-year OS of 72% (95% CI: 63-79%) and 76% (95% CI:67-83%) were 
observed in the cohort treated with eight and six cycles, respectively. Consistently, no 
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evidence of a difference was observed in a multivariate analysis (HR with six cycles: 0.88 
(95% CI: 0.54-1.44), P=0.62). 
Additionally, no evidence of a difference in outcome according to use of six or eight cycles of 
R-CHOP-21 were observed in subgroup analyses stratified according to age ≤/>70, low and 
high-risk IPI score, and excluding patients treated with consolidative radiotherapy. 
These results are in line with results from the ECOG/CALGB 9703 study, where the outcome 
of patients who received six cycles of R-CHOP-21 were comparable to those of patients with 
similar patient characteristics treated with eight cycles in the GELA study [1, 2].  
The RICOVER-60 trial demonstrated increased toxicity in absence of improved outcome with 
eight compared to six cycles of R-CHOP-14 [5]. However, only elderly patients (aged 60-80) 
were included and a similar comparison of R-CHOP-21 has not been performed. Thus, the 
present study contributes valuable data regarding the use of six cycles of R-CHOP-21 among 
patients of all ages and risk groups. 
In summary, we note that the majority of patients with DLBCL treated with R-CHOP-21 
during the surveyed time period received six cycles, and conclude that outcomes following six 
or eight cycles of R-CHOP-21 for newly diagnosed DLBCL are comparable in terms of 
efficacy.  
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Figure 1: Overall survival for patients treated with 6 (red line) and 8 (green line) cycles of R-
CHOP-21. 
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Figure 1: Overall survival for patients treated with 6 (red line) and 8 (green line) cycles of R-CHOP-21.  
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